Injectable Hormones Market By Types of Hormones (Sex Hormones {Estrogen, Progesterone, Testosterone}, Metabolic Hormones {Insulin, Glucagon}, Growth Hormones {Human Growth Hormone (HGH), Erythropoietin (EPO)}, Corticosteroids {Hydrocortisone, Prednisolone}, Endocrine Hormones {Parathyroid Hormone, Thyroid Hormone}, Others), By Application (Hormone Replacement Therapy (HRT), Fertility Treatment, Gender Dysphoria Treatment, Endocrine Disorders, Oncology, Anti-aging and Wellness, Osteoporosis, Others), By Route of Administration (Subcutaneous Injection, Intramuscular Injection, Intravenous Injection), By End-User (Hospitals, Clinics, Homecare Settings, Specialty Centers, Ambulatory Surgical Centers), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Industry Outlook

The Injectable Hormones market accounted for USD 18.3 Billion in 2024 and is expected to reach USD 36.6 Billion by 2035, growing at a CAGR of around 6.5% between 2025 and 2035. Injectable hormones refer to drugs that are administered through injections for hormonal therapy. Different medical needs are fulfilled through such hormonal treatment drugs. Insulin, the drug used to correct diabetes, is one of the commonly administered hormones. Another hormone, human growth hormone, deals with growth disorders, while sex hormones include testosterone and estrogen, which are administered to treat hormonal imbalances.

The injectable hormones market will see an increase in demand because of the rising prevalence of hormonal disorders, increased awareness of these treatment options, and advances in drug delivery technologies. The geographic trend indicates different levels of demand based on the availability of access to health care and the regulatory environment. However, costly treatment procedures and potential side effects also impact patient compliance. Generally, this market plays a prime role in the modern age of health care, offering timely cures to most hormonal disorder patients.

Report Scope:

Market Dynamics

Increased incidences of conditions like diabetes and thyroid disorders boost demand for hormone therapies.

The rising number of cases of diabetes and thyroid disorders considerably boosts the demand for injectable hormone therapies across the globe which drives the injectable hormones market growth. Metabolic disorders are commonly seen due to an improper lifestyle. Patients are thus demanding effective management strategies. Injectable hormones, such as insulin for diabetes and, for hypothyroidism, thyroid hormones, deliver rapid and precise therapeutic options to improve patient outcomes.

According to the American Thyroid Association, over 12% of the U.S. population will have a form of a thyroid condition during their lifetime. Roughly 20 million Americans suffer from a form of thyroid disease. Up to 60% of them are unaware that they are suffering from it. More awareness of hormone-related health issues drives more people to seek medical interventions with other enablers including improved drug technologies that have boosted the efficacy and safety of these therapies.

Hormones are being used in various therapeutic areas, including reproductive health and cancer treatment.

The use of injectable hormones across various therapeutic areas, particularly in reproductive health and cancer treatment, is a significant driver for the injectable hormones market. Luteinizing hormone and follicle-stimulating hormone are the crucial hormones of reproductive health in the treatment of fertilization and hormone replacement therapies.

According to the American Cancer Society, it is projected that about 1.9 million new cancer cases will occur in the United States in the year 2023. This demand is fed by advancements in clinical practices and increased appreciation of the role hormones play in the treatment protocol. This is mainly because injectable hormones are being increasingly used in a wide range of therapeutic fields and thus contribute to the development of the market, crucial for modern medicine.

Fear of potential dependency on hormone therapies may discourage usage.

The fear of potential dependency on hormone therapies poses a significant restraint for the injectable hormones market. Many patients worry that hormone therapy can have long-term consequences. Such an outlook may deter some patients from beginning their treatment or from completing their prescribed treatment programs.

These fear factors may also be linked to hormone imbalances or withdrawal symptoms after stopping the drug. Because of the reliance and numerous other issues that come with injectable hormones, providers are also likely to be extremely cautious when making recommendations. The stigma around hormone therapy, therefore, may limit market growth. Patients and health practitioners alike seek alternative treatments that may seem less risky or more natural.

Tailoring hormone therapies based on genetic profiles presents a significant growth opportunity.

Tailoring hormone therapies based on genetic profiles represents a significant growth opportunity for the injectable hormones market. Personalized medicine is going to change the interaction between the patient's genome and hormones to introduce effective, targeted, and person-specific results with optimized results, minimal side effects, and high adherence by healthcare providers. Increasing the efficacy of injectable hormones would help satisfy the rising need for individualized healthcare solutions.

Furthermore, including genetic tests in the treatment plans would help detect the patients at risk of adverse reactions and would increase further confidence in hormone therapies. With continued research and developments in genomics and advanced technologies, the possibility of hormone therapies that are better designed according to specific individuals increases, which allows healthy growth in the injectable hormone market in the following years.

Combining hormone therapies with telehealth solutions can improve monitoring and adherence.

The combination of hormone therapies and telehealth solutions would open a new opportunity for the injectable hormones market in connection with stronger patient monitoring and adherence. It is possible to use telehealth platforms to hold virtual consultations with patients, thus monitoring the developments frequently and making timely alterations in the treatment plan without an in-person visit. This actually can enhance patient engagement, as it would make it easier for patients to discuss with healthcare providers their experiences and concerns related to their hormone therapies.

Integrated digital tools can allow for reminders of injections and tracking patient progress, but again, telehealth may be utilized by providers to offer more tailored support, which will ultimately help in better health outcomes and higher patient satisfaction. The rising acceptance of telehealth is also likely to boost the treatment of hormonal disorders with the growth of the market.

Industry Experts Opinion

“In India, hormone therapy is becoming increasingly popular as women seek to manage the symptoms of menopause. Many women are turning to this therapy as a safe and effective way to manage their symptoms and improve overall health,”

• Dr Vaishali Sharma, laparoscopic surgeon and IVF specialist

Segment Analysis

Based on the type of hormones, the Injectable Hormones Market has been classified into Sex Hormones, Metabolic Hormones, Growth Hormones, Corticosteroids, Endocrine Hormones, and Others. In the injectable hormones market, sex hormones are the dominant significant segment. This prominence is due to the increasing demand for hormone replacement therapies and treatments concerning different hormonal disorders.

Menopause and testosterone deficiency are treated with hormone replacement therapies and treatments. Their growing awareness of the benefits of hormones towards overall well-being and quality of life also adds to their prominence. With the increase in patients requiring personalized treatment, the injectable sex hormone market is growing and will continue to grow due to both therapeutic and aesthetic needs. Therefore, the rise in the market represents an increasingly important role of sex hormones in healthcare.

Based on the type of hormones, the Injectable Hormones Market has been classified into Hormone Replacement Therapy (HRT), Fertility Treatment, Gender Dysphoria Treatment, Endocrine Disorders, Oncology, Anti-aging and Wellness, Osteoporosis, and Others. In the injectable hormones market, hormone replacement therapy (HRT) is the most prominent segment. The increasing prevalence of hormonal imbalances, especially among aging populations, will continue to fuel demand for HRT solutions that alleviate symptoms of menopause and andropause. There has also been increasing awareness of the therapeutic benefits of HRT in enhancing the quality of life and, subsequently, its adoption. As more healthcare providers prescribe personalized HRT regimens, this segment is expected to continue its growth as a dominant force in the injectable hormone market. 

Regional Analysis

The North American injectable hormone market is rapidly expanding. A well-advanced healthcare infrastructure and an established biopharmaceutical sector add a positive level of support to this growth. The awareness about hormone replacement therapies for menopause and deficiency of growth hormones is increasing and enhancing the rate of adoption. Strong health expenditure in the U.S. and Canada and supportive regulations for new hormone products also support the region in the enhancement of the rate of adoption. Research benefits and investment strength towards new drug development place the region firmly in top positions in the global market.

The United States hosts the largest share of North America's injectable hormones market because of its developed healthcare system, large-scale biopharmaceutical industry, and emphasis on research and development. The developed regulatory environment, along with fast-track approvals for innovative treatments, leads to expansion in this North American injectable hormone market. The adoption of hormone replacement therapies is further encouraged among the aged and menopausal women, which further boosts growth.

The European injectable hormone market is proliferating due to an increasing prevalence of hormonal disorders and an aging population. The major players focus more on product innovation and advancements in drug delivery systems to improve compliance. Because of the regulatory structure, there is a high degree of safety and efficacy in this area, which increases consumer confidence. Thus, the rise of personalized medicine and diagnosis defines the market. Geographical differences also affect market trends and costs in different nations. Strategically, collaborations and mergers of pharmaceutical companies are also expected to expand the market through more product offerings.

Germany is witnessing a growth trend in its injectable hormones market. The healthcare delivery mechanism in the country is quite remarkable. Innovations in drug delivery systems are very common in Germany. German regulations are very strict on safety and efficacy to provide optimum security to patients and their providers. The key players are catering to research and development efforts to improve treatments. Companies joining forces increase the prospects of growth in the market. All in all, Germany showcases a competitive landscape with immense potential.

Competitive Landscape

The injectable hormones market is very competitive, with major global players such as Pfizer, Novo Nordisk, Eli Lilly, and Sanofi ruling the market due to strong product portfolios, regulatory expertise, and capabilities of global distribution. Demand for hormone replacement therapies, fertility treatments, insulin, and growth hormones will continue to propel the market further since cases of hormone-related disorders such as diabetes and imbalances in endocrine are on the increase.

The company has been trying to move ahead in its formulations, which now include long-acting injectables. Due to patent expirations, biosimilars have increased the competition lately, and new entrants are encroaching on the market share of well-established brands. Moreover, governmental regulatory approvals and technological advancements in the drug delivery systems challenge the companies to offer something distinctive.

Injectable Hormones Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In November 2023, The FDA approved Lilly's Zepbound™ (tirzepatide) for chronic weight management, providing a new and effective treatment option for obesity and overweight individuals facing weight-related health issues.

Report Coverage:

By Types of Hormones

• Sex Hormones:
  • Estrogen
  • Progesterone
  • Testosterone
• Metabolic Hormones
  • Insulin
  • Glucagon
• Growth Hormones
  • Human Growth Hormone (HGH)
  • Erythropoietin (EPO)
• Corticosteroids
  • Hydrocortisone
  • Prednisolone
• Endocrine Hormones
  • Parathyroid Hormone
  • Thyroid Hormone
• Others

By Application

• Hormone Replacement Therapy (HRT):
• Fertility Treatment
• Gender Dysphoria Treatment
• Endocrine Disorders
• Oncology:
• Anti-aging and Wellness:
• Osteoporosis
• Others

By Route of Administration

• Subcutaneous Injection
• Intramuscular Injection
• Intravenous Injection

End-User

• Hospitals
• Clinics
• Homecare Settings
• Specialty Centers
• Ambulatory Surgical Centers

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies:

• Pfizer
• Novo Nordisk
• Eli Lilly and Company
• Merck & Co.
• Sanofi
• Teva Pharmaceuticals
• Ferring Pharmaceuticals
• Bayer AG
• Mylan
• Ipsen
• AbbVie
• Endo International
• Organon & Co.
• Novartis
• Genentech
• AstraZeneca

Frequently Asked Questions (FAQs)